 - Anti-tumor therapy chemotherapy, antibody therapy, molecular targeted therapy, retinoid therapy, hormonal therapy, or investigational agent within 28 days of study day 1 six weeks for nitrosureas, mitomycin C, or antibody or molecular targeted agents with t12 10 days; concurrent use of hormone deprivation therapy for hormone-refractory prostate cancer or breast cancer is permitted 